scholarly journals Autologous Hematopoietic Stem Cell Transplantation Modulates Immunocompetent Cells and Improves β-Cell Function in Chinese Patients with New Onset of Type 1 Diabetes

2012 ◽  
Vol 97 (5) ◽  
pp. 1729-1736 ◽  
Author(s):  
Lirong Li ◽  
Shanmei Shen ◽  
Jian Ouyang ◽  
Yun Hu ◽  
Limin Hu ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Cell Function ◽  
Chinese Patients ◽  
Β Cell ◽  
Hematopoietic Stem ◽  
Β Cell Function ◽  
New Onset

β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial

The Lancet ◽  
2001 ◽  
Vol 358 (9295) ◽  
pp. 1749-1753 ◽  
Author(s):  
Itamar Raz ◽  
Dana Elias ◽  
Ann Avron ◽  
Merana Tamir ◽  
Muriel Metzger ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Cell Function ◽  
Phase Ii Trial ◽  
Β Cell ◽  
Double Blind ◽  
Β Cell Function ◽  
New Onset

An economic analysis of autologous hematopoietic stem cell transplantation (AHSCT) in the treatment of new onset type 1 diabetes

2015 ◽  
Vol 52 (5) ◽  
pp. 881-888 ◽  
Author(s):  
Emilian Snarski ◽  
Daria Szmurło ◽  
Kazimierz Hałaburda ◽  
Małgorzata Król ◽  
Elżbieta Urbanowska ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Economic Analysis ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem ◽  
New Onset

scholarly journals Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1cin New-Onset Type 1 Diabetes

Diabetes Care ◽  
2018 ◽  
Vol 41 (9) ◽  
pp. 1917-1925 ◽  
Author(s):  
Michael J. Haller ◽  
Desmond A. Schatz ◽  
Jay S. Skyler ◽  
Jeffrey P. Krischer ◽  
Brian N. Bundy ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Low Dose ◽  
Cell Function ◽  
Β Cell ◽  
Onset Type ◽  
Β Cell Function ◽  
New Onset

scholarly journals Updates on Immune Therapies in Type 1 Diabetes

2016 ◽  
Vol 12 (2) ◽  
pp. 89 ◽  
Author(s):  
Bimota Nambam ◽  
◽  
Michael J Haller ◽  
Keyword(s):  
Clinical Trials ◽  
Type 1 Diabetes ◽  
Cell Function ◽  
Β Cell ◽  
Immune Therapies ◽  
Β Cell Function ◽  
Potential Benefits ◽  
New Onset

Multiple clinical trials investigating the efficacy and safety of immunotherapeutic interventions in new onset type 1 diabetes (T1D) have failed to yield long term clinical benefit. Lack of efficacy has frequently been attributed to an incomplete understanding of the pathways involved in T1D and the use of single immunotherapeutic agents. Recent mechanistic studies have improved our knowledge of the complex etiopathogenesis of T1D. This in turn has provided the framework for new and ongoing clinical trials in new onset T1D patients and at-risk subjects. Focus has also shifted towards the potential benefits of synergistic combinatorial approaches, both in terms of efficacy and the potential for reduced side effects. These efforts seek to develop intervention strategies that will preserve β-cell function, and ultimately prevent and reverse clinical disease.

Tapering decay of β‐cell function in Chinese patients with autoimmune type 1 diabetes: A four‐year prospective study

2019 ◽  
Vol 11 (10) ◽  
pp. 802-808 ◽  
Author(s):  
Xia Li ◽  
Jin Cheng ◽  
Gan Huang ◽  
Shuoming Luo ◽  
Zhiguang Zhou
Keyword(s):  
Type 1 Diabetes ◽  
Prospective Study ◽  
Cell Function ◽  
Chinese Patients ◽  
Β Cell ◽  
Β Cell Function

scholarly journals 100 years post insulin: immunotherapy as the next frontier in Type 1 Diabetes

2021 ◽  
Author(s):  
James A Pearson ◽  
Eoin F McKinney ◽  
Lucy S K Walker
Keyword(s):  
Type 1 Diabetes ◽  
Autoimmune Disease ◽  
Turning Point ◽  
Cell Function ◽  
Β Cells ◽  
Β Cell ◽  
Β Cell Function ◽  
Selection Of ◽  
New Onset

Abstract Type 1 diabetes (T1D) is an autoimmune disease characterised by T cell-mediated destruction of the insulin-producing β cells in the pancreas. Similar to other autoimmune diseases, the incidence of T1D is increasing globally. The discovery of insulin 100 years ago dramatically changed the outlook for people with T1D, preventing this from being a fatal condition. As we celebrate the centenary of this milestone, therapeutic options for T1D are once more at a turning point. Years of effort directed at developing immunotherapies are finally starting to pay off, with signs of progress in new onset and even preventative settings. Here we review a selection of immunotherapies that have shown promise in preserving β cell function and highlight future considerations for immunotherapy in the T1D setting.

Sign in / Sign up

Export Citation Format

Share Document